CARA Projected Dividend Yield
Cara Therapeutics Inc ( NASDAQ : CARA )Cara Therapeutics, Inc. is a development-stage biopharmaceutical company. Co. is focused on treatment paradigm to improve the lives of patients suffering from chronic pruritus. It is developing an oral formulation of difelikefalin, a selective, predominantly peripherally acting, non-scheduled Kappa opioid receptor agonist, for the treatment of chronic neuropathic pruritus associated with Notalgia Paresthetica (NP), a common, underdiagnosed neuropathy affecting the upper back. It is conducting Phase II/III Clinical Program in NP. 20 YEAR PERFORMANCE RESULTS |
CARA Dividend History Detail CARA Dividend News CARA Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |